Hong Kong Stock Exchange · Healthcare
Invest in Cloudbreak Pharma stock from India
Indian and foreign residents can buy Cloudbreak Pharma (2592) shares directly through Paasa.
By Paasa · Updated
Cloudbreak Pharma at a glance
- Price
- HK$1.19+HK$0.03 (2.15%)
- Market cap
- HK$1.05B
- Day range
- HK$1.19 – HK$1.19
- P/E
- —
- Dividend yield
- None
- Volume
- 18.50K
- 1 month
- -0.83%
- 6 months
- -29.17%
- YTD
- -76.57%
- 1 year
- -74.02%
- 5 years
- -80.81%
How to invest in Cloudbreak Pharma from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 2592 and buy
Find Cloudbreak Pharma by name or by its ticker, 2592, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Cloudbreak Pharma from India
What Cloudbreak Pharma does
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that… Cloudbreak Pharma operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Cloudbreak Pharma stock from India?
Yes. Indian residents and NRIs can buy Cloudbreak Pharma (2592) shares directly through Paasa. Cloudbreak Pharma is listed on the Hong Kong Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Cloudbreak Pharma share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$1.19 a share, size the order by the lot, not by the share.
How are Cloudbreak Pharma dividends taxed for Indian investors?
Cloudbreak Pharma trades on the Hong Kong Stock Exchange but is domiciled in United States, so any withholding on its dividends follows that country's rules rather than those of Hong Kong. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Cloudbreak Pharma shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.